Sensitizing osteosarcoma stem cells to doxorubicin-induced apoptosis through retention of doxorubicin and modulation of apoptotic-related proteins

Life Sciences

Volumn 130, Issue , 2015, Pages 47-56

  Gonçalves, Cláudia ^a   Martins Neves, Sara R ^a   Paiva Oliveira, Daniela ^a   Oliveira, Vitor E B ^a   Fontes Ribeiro, Carlos ^a   Gomes, Célia M F ^a,b  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

Apoptosis; BCRP; Cancer stem cells; Chemoresistance; Doxorubicin; Osteosarcoma; P glycoprotein

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CASPASE 3; CASPASE 7; DOXORUBICIN; MULTIDRUG RESISTANCE PROTEIN; PROTEIN BAK; PROTEIN BCL 2; PROTEIN BCL XL; VERAPAMIL; ANTINEOPLASTIC ANTIBIOTIC; APOPTOSIS REGULATORY PROTEIN;

APOPTOSIS; ARTICLE; BIOLUMINESCENCE; BRDU ASSAY; CANCER STEM CELL; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DOWN REGULATION; DRUG POTENTIATION; DRUG SENSITIZATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; MTT ASSAY; NICK END LABELING; OSTEOSARCOMA CELL; UPREGULATION; WESTERN BLOTTING; BONE NEOPLASMS; DRUG EFFECTS; DRUG RESISTANCE; METABOLISM; OSTEOSARCOMA; PATHOLOGY; TUMOR CELL LINE;

ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BLOTTING, WESTERN; BONE NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; DOWN-REGULATION; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; HUMANS; MICROSCOPY, CONFOCAL; NEOPLASTIC STEM CELLS; OSTEOSARCOMA; P-GLYCOPROTEIN; UP-REGULATION;

EID: 84927731861     PISSN: 00243205     EISSN: 18790631     Source Type: Journal    
DOI: 10.1016/j.lfs.2015.03.009     Document Type: Article

References (36)

1. A. Longhi, C. Errani, M. De Paolis, M. Mercuri, and G. Bacci Primary bone osteosarcoma in the pediatric age: state of the art Cancer Treat. Rev. 32 2006 423 436 10.1016/j.ctrv.2006.05.005
2. N. Marina, M. Gebhardt, L. Teot, and R. Gorlick Biology and therapeutic advances for pediatric osteosarcoma Oncologist 9 2004 422 441 10.1634/theoncologist.9-4-422
3. G. Gatta, R. Capocaccia, C. Stiller, P. Kaatsch, F. Berrino, M. Terenziani, and the EUROCARE Working Group Childhood cancer survival trends in europe: a EUROCARE Working Group Study J. Clin. Oncol. 23 2005 3742 3751 10.1200/JCO.2005.00.554
4. S. Ferrari, A. Briccoli, M. Mercuri, F. Bertoni, P. Picci, A. Tienghi, A.B. Del Prever, F. Fagioli, A. Comandone, and G. Bacci Postrelapse survival in osteosarcoma of the extremities: prognostic factors for long-term survival J. Clin. Oncol. 21 2003 710 715 10.1200/JCO.2003.03.141
5. J.E. Visvader, and G.J. Lindeman Cancer stem cells: current status and evolving complexities Cell Stem Cell 10 2012 717 728 10.1016/j.stem.2012.05.007
6. M. Diehn, R.W. Cho, and M.F. Clarke Therapeutic implications of the cancer stem cell hypothesis Semin. Radiat. Oncol. 19 2009 78 86 10.1016/j.semradonc.2008.11.002
7. S. Martins-Neves, A. Lopes, A. do Carmo, A. Paiva, P. Simoes, A. Abrunhosa, and C. Gomes Therapeutic implications of an enriched cancer stem-like cell population in a human osteosarcoma cell line BMC Cancer 12 2012 139 10.1186/1471-2407-12-139
8. K. Honoki, H. Fujji, A. Kubo, A. Kido, T. Mori, Y. Tanaka, and T. Tsujiuchi Possible involvement of stem-like populations with elevated ALDH1 in sarcomas for chemotherapeutic drug resistance Oncol. Rep. 24 2010 501 505 10.3892/or-00000885
9. V. Tirino, V. Desiderio, F. Paino, A. De Rosa, F. Papaccio, F. Fazioli, G. Pirozzi, and G. Papaccio Human primary bone sarcomas contain CD133 + cancer stem cells displaying high tumorigenicity in vivo FASEB J. 25 2011 2022 2030 10.1096/fj.10-179036
10. J.A. McCubrey, S.L. Abrams, T.L. Fitzgerald, L. Cocco, A.M. Martelli, G. Montalto, M. Cervello, A. Scalisi, S. Candido, M. Libra, and L.S. Steelman Roles of signaling pathways in drug resistance, cancer initiating cells and cancer progression and metastasis Adv. Biol. Regul. 2014 1 27 10.1016/j.jbior.2014.09.016
11. N. Takebe, P.J. Harris, R.Q. Warren, and S.P. Ivy Targeting cancer stem cells by inhibiting Wnt, notch, and hedgehog pathways Nat. Rev. Clin. Oncol. 8 2011 97 106 10.1038/nrclinonc.2010.196
12. S. Fulda Regulation of apoptosis pathways in cancer stem cells Cancer Lett. 338 2013 168 173 10.1016/j.canlet.2012.03.014
13. S.W. Lowe, E. Cepero, and G. Evan Intrinsic tumour suppression Nature 432 2004 307 315 10.1038/nature03098
14. W.P. Tsang, S.P.Y. Chau, S.K. Kong, K.P. Fung, and T.T. Kwok Reactive oxygen species mediate doxorubicin induced p53-independent apoptosis Life Sci. 73 2003 2047 2058 10.1016/S0024-3205(03)00566-6
15. J. Dembinski, and S. Krauss Characterization and functional analysis of a slow cycling stem cell-like subpopulation in pancreas adenocarcinoma Clin. Exp. Metastasis 26 2009 611 623 10.1007/s10585-009-9260-0
16. P.N. Kelly, and A. Strasser The role of Bcl-2 and its pro-survival relatives in tumourigenesis and cancer therapy Cell Death Differ. 18 2011 1414 1424 10.1038/cdd.2011.17
17. K.W. Yip, and J.C. Reed Bcl-2 family proteins and cancer Oncogene 27 2008 6398 6406 10.1038/onc.2008.307
18. T. Reya, A.W. Duncan, L. Ailles, J. Domen, D.C. Scherer, K. Willert, L. Hintz, R. Nusse, and I.L. Weissman A role for Wnt signalling in self-renewal of haematopoietic stem cells Nature 423 2003 409 414 10.1038/nature01593
19. K. Kemper, H. Rodermond, S. Colak, C. Grandela, and J. Medema Targeting colorectal cancer stem cells with inducible caspase-9 Apoptosis 17 2012 528 537 10.1007/s10495-011-0692-z
20. K.E. Tagscherer, A. Fassl, B. Campos, M. Farhadi, A. Kraemer, B.C. Bock, S. Macher-Goeppinger, B. Radlwimmer, O.D. Wiestler, C. Herold-Mende, and W. Roth Apoptosis-based treatment of glioblastomas with ABT-737, a novel small molecule inhibitor of Bcl-2 family proteins Oncogene 27 2008 6646 6656 10.1038/onc.2008.259
21. G. Liu, X. Yuan, Z. Zeng, P. Tunici, H. Ng, I. Abdulkadir, L. Lu, D. Irvin, K. Black, and J. Yu Analysis of gene expression and chemoresistance of CD133 + cancer stem cells in glioblastoma Mol. Cancer 5 2006 67 10.1186/1476-4598-5-67
22. R.W. Johnstone, E. Cretney, and M.J. Smyth P-glycoprotein protects leukemia cells against caspase-dependent, but not caspase-independent, cell death Blood 93 1999 1075 1085
23. M.Q. Gao, Y.P. Choi, S. Kang, J.H. Youn, and N.H. Cho CD24 + cells from hierarchically organized ovarian cancer are enriched in cancer stem cells Oncogene 29 2010 2672 2680 10.1038/onc.2010.35
24. G. Naumov, J. Townson, I. MacDonald, S. Wilson, V. Bramwell, A. Groom, and A. Chambers Ineffectiveness of doxorubicin treatment on solitary dormant mammary carcinoma cells or late-developing metastases Breast Cancer Res. Treat. 82 2003 199 206 10.1023/B:BREA.0000004377.12288.3c
25. T. Panaretakis, K. Pokrovskaja, M.C. Shoshan, and D. Grandér Activation of Bak, Bax, and BH3-only proteins in the apoptotic response to doxorubicin J. Biol. Chem. 277 2002 44317 44326 10.1074/jbc.M205273200
26. G.Q. Wang, B.R. Gastman, E. Wieckowski, L.A. Goldstein, A. Gambotto, T.H. Kim, B. Fang, A. Rabinovitz, X.M. Yin, and H. Rabinowich A role for mitochondrial Bak in apoptotic response to anticancer drugs J. Biol. Chem. 276 2001 34307 34317 10.1074/jbc.M103526200
27. C. Castilla, B. Congregado, D. Chinchón, F.J. Torrubia, M.A. Japón, and C. Sáez Bcl-xL is overexpressed in hormone-resistant prostate cancer and promotes survival of LNCaP cells via interaction with proapoptotic Bak Endocrinology 147 2006 4960 4967 10.1210/en.2006-0502
28. M. Konopleva, S. Zhao, W. Hu, S. Jiang, V. Snell, D. Weidner, C.E. Jackson, X. Zhang, R. Champlin, E. Estey, J.C. Reed, and M. Andreeff The anti-apoptotic genes Bcl-XL and Bcl-2 are over-expressed and contribute to chemoresistance of non-proliferating leukaemic CD34 + cells Brit. J. Haematol. 118 2002 521 534 10.1046/j.1365-2141.2002.03637.x
29. M.M. Gottesman, T. Fojo, and S.E. Bates Multidrug resistance in cancer: role of ATP-dependent transporters Nat. Rev. Cancer 2 2002 48 58 10.1038/nrc706
30. K. Moitra, H. Lou, and M. Dean Multidrug efflux pumps and cancer stem cells: insights into multidrug resistance and therapeutic development Clin. Pharmacol. Ther. 89 2011 491 502 10.1038/clpt.2011.14
31. C.M.F. Gomes, H. van Paassen, S. Romeo, M.M. Welling, R.I.J. Feitsma, A.J. Abrunhosa, M.F. Botelho, P.C.W. Hogendoorn, E. Pauwels, and A.M. Cleton-Jansen Multidrug resistance mediated by ABC transporters in osteosarcoma cell lines: mRNA analysis and functional radiotracer studies Nucl. Med. Biol. 33 2006 831 840 10.1016/j.nucmedbio.2006.07.011
32. M. Serra, M. Pasello, M.C. Manara, K. Scotlandi, S. Ferrari, F. Bertoni, M. Mercuri, T.A. Alvegard, P. Picci, G. Bacci, and S. Smeland May P-glycoprotein status be used to stratify high-grade osteosarcoma patients? Results from the Italian/Scandinavian Sarcoma Group 1 treatment protocol Int. J. Oncol. 29 2006 1459 1468 10.3892/ijo.29.6.1459
33. J.Q. Cheng, C.W. Lindsley, G.Z. Cheng, H. Yang, and S.V. Nicosia The Akt/PKB pathway: molecular target for cancer drug discovery Oncogene 24 2005 7482 7492 10.1038/sj.onc.1209088
34. D. Opel, M.A. Westhoff, A. Bender, V. Braun, K.M. Debatin, and S. Fulda Phosphatidylinositol 3-kinase inhibition broadly sensitizes glioblastoma cells to death receptor- and drug-induced apoptosis Cancer Res. 68 2008 6271 6280 10.1158/0008-5472.CAN-07-6769
35. D. Marklein, U. Graab, I. Naumann, T. Yan, R. Ridzewski, F. Nitzki, A. Rosenberger, K. Dittmann, J. Wienands, L. Ojnowski, S. Ulda, and H. Ahn PI3K inhibition enhances doxorubicin-induced apoptosis in sarcoma cells PLoS ONE 7 2012 e52898 10.1371/journal.pone.0052898
36. Y. Imai, M. Yoshimori, K. Fukuda, H. Yamagishi, and Y. Ueda The PI3K/Akt inhibitor LY294002 reverses BCRP-mediated drug resistance without affecting BCRP translocation Oncol. Rep. 27 2012 1703 1709 10.3892/or.2012.1724